Methods:
We included consecutive patients who presented to a teaching hospital in Germany with chest pain of cardiac origin confirmed by coronary angiography. We analyzed PAPP-A levels from serum samples drawn within 30 minutes after arrival in the emergency department or in the catheterization laboratory. Patients were followed for 90 days or until death for major adverse cardiovascular events, defined as the combined outcome of stent thrombosis, myocardial (re)infarction, ischemic stroke or cardiovascular-related death.
Results: A total of 2568 patients (mean age [± standard deviation (SD)] 68 ± 11 years; 74% male) presented with cardiac chest pain: 55% had stable angina and 45% had acute coronary syndrome. The PAPP-A levels ranged from 4 to 2154 mIU/L (median 14.0 mIU/L, interquartile range 9.3-25.2 mIU/L). Major adverse cardiovascular events occurred in 203 patients (7.9%). The mean PAPP-A level was higher among patients who had an event than among those who did not (62 ± 156 v. 21 ± 23 mIU/L, p < 0.001). In a multivariable analysis, PAPP-A remained a significant independent predictor of the primary outcome within 90 days (hazard ratio per 1 SD increase in PAPP-A level 1.96, 95% confidence interval 1.74-2.21). The optimal prognostic cutoff value was a PAPP-A level of 34.6 mIU/L.
events in a large sample of 2568 consecutive patients who presented with cardiac chest pain.
Methods

Patient selection
We evaluated consecutive patients who presented with chest pain to the University Hospital Tübin-gen, Germany, between December 2007 and April 2009. A cardiac cause of chest pain was assumed unless proven otherwise and was confirmed with coronary angiography.
Clinical evaluation
All patients underwent coronary angiography within 24 hours after arrival, either for suspected acute coronary syndrome or as part of an elective admission in patients with stable angina. Acute coronary syndrome was defined according to the joint guidelines of the American Heart Association and the American College of Cardiology, 13 with a diagnostic threshold for troponin I of 0.04 ng/mL or higher. Stable angina pectoris was defined as symptoms of angina pectoris without progression and with stable intensity and a troponin I level below 0.04 ng/mL before cardiac catheterization.
All patients underwent echocardiography within 48 hours after initial presentation. The degree of left ventricular impairment was classified according to the left ventricular ejection fraction: severe impairment (left ventricular ejection fraction < 35%), moderate impairment (35%-44%), mild impairment (45%-59%) or no impairment (≥ 60%).
All patients were followed up by telephone interview or outpatient office visit for 90 days or until death. No patient was lost to follow-up.
Biochemical analysis
Venous blood was drawn from an antecubital vein for routine clinical assessments and as part of a prospective biomarker research project. For our study, we excluded patients who had blood samples collected after the administration of heparin, because PAPP-A is known to interact with heparin.
14 Serum samples were immediately centrifuged and stored at -80°C for later analysis.
We analyzed serum values of creatine kinase, C-reactive protein and creatinine using standard laboratory assays. Troponin I was analyzed using a highly sensitive assay (Troponin I-Ultra assay on the ADVIA Centaur immunoanalyzer, Siemens AG, Eschborn, Germany). If more than one measurement was available for the entire hospital stay, the respective peak values were entered into the analysis. For PAPP-A assessment, an additional blood sample was filled into 5-mL pyrogen-free serum vials. Blood samples for PAPP-A analysis were drawn within 30 minutes after arrival to the emergency department or in the catheterization laboratory, whichever came first. PAPP-A serum values were analyzed using an automated immunofluorescent assay (Kryptor PAPP-A automated immunofluorescent assay, Thermo Fisher Scientific, BRAHMS GmbH, Hennigsdorf, Germany). The functional assay sensitivity (inter assay coefficient of variance < 3%) is 4 mIU/L. According to the manufacturer, the normal serum value in men and nonpregnant women is < 14 mIU/L. Physicians involved in caring for the patients or who performed follow-up investigations were unaware of the respective PAPP-A serum values.
Ethics approval
The study design was approved by the Clinical Ethics Committee of the University Hospital Tübingen, and all patients provided written informed consent.
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CMAJ
Presented with chest pain n = 4038
Presented with cardiac chest pain n = 2700
Included in analysis n = 2568
Excluded n = 1338
• Noncardiac chest pain (arterial hypertension, orthopedic origin, acute pulmonary embolism, Da Costa syndrome)
Excluded n = 132
• Data incomplete n = 122 • Received heparin before blood sampling n = 10
Stable angina n = 1339
Acute coronary syndrome n = 1229
• Unstable angina n = 101
• Non-ST-segment elevation myocardial infarction n = 777 • ST-segment elevation myocardial infarction n = 337 • Cardiogenic shock n = 14 
Outcome measure
The primary outcome measure was a combined outcome of stent thrombosis, myocardial (re)infarction, ischemic stroke or cardiovascularrelated death.
Statistical analysis
Data are expressed as mean ± standard deviation (SD). Normal distribution was assessed using the Kolmogorov-Smirnov test, and non-normally distributed data were log-transformed to achieve normal distribution. We used the χ 2 test, Student unpaired t-test, and analysis of variance with the Fisher predicted least significant difference (post hoc) test to compare differences between groups. Univariable regression analyses were performed to assess factors that independently predicted PAPP-A levels. The association of baseline variables with survival was assessed by means of Cox proportional hazard analysis (single predictor and multivariable analysis). Hazard ratios (HRs) and 95% confidence intervals (CIs) for risk factors and significance level for χ 2 (likelihood ratio test) were calculated. For variables that were included twice in the unadjusted model (as log and continuous variables), the variable with the higher level of significance in the unadjusted model, as judged by the χ 2 value, was chosen for the multivariable model. To estimate the influence of risk factors on the occurrence of the primary outcome at 90 days, we constructed Kaplan-Meier cumulative survival curves for illustrative purposes and compared them using the log-rank test. The optimal prognostic cut-off value was defined as the highest product of sensitivity multiplied by specificity. In all analyses, †For comparison between patients with stable angina and those with acute coronary syndrome (analysis of variance, Student t-test or χ 2 test).
a value of p < 0.05 was considered significant. Statistics were calculated using StatView 5.0 software for Windows (Abacus Concepts, Berkley, California).
Results
Of 4038 consecutive patients presenting with chest pain, 2700 were confirmed by coronary angiography to have cardiac chest pain ( Figure 1 ). Inclusion criteria were met by 2568 of these patients. The median time between onset of chest pain and hospital admission was 2.5 hours.
The patients' clinical characteristics are presented in Table 1 ; their medical history and use of medications are provided in Table 2 . A total of 1339 (52.1%) patients were classified as having stable angina and the remainder as having acute coronary syndrome. The precise diagnoses are shown in Figure 1 . We detected significant differences between patients with stable angina and those with acute coronary syndrome in terms of body mass index (BMI), and serum levels of Creactive protein, troponin I, creatine kinase and creatinine (p < 0.001 in each case). The impairment of left ventricular function was significantly more pronounced in patients with acute coronary syndrome than in those with stable angina (p < 0.001).
Serum levels of PAPP-A were available for all of the patients. The mean level was 24. Table 3 . A total of 203 (7.9%) of the patients had 245 primary outcome events during the 90 days of follow-up: stent thrombosis (58 events), myocardial (re)infarction (98 events), ischemic stroke (18 events) and cardiovascular-related death (71 events). Patients who experienced a primary outcome had a mean PAPP-A level of 62.0 ± 156.4 mIU/L, as compared with 21.4 ± 22.8 mIU/L among those who did not (p < 0.001). No difference in outcome was detected between patients with stable angina and any of the subgroups of patients with acute coronary syndrome (p trend = 0.09).
Several dichotomized and continuous variables were investigated to determine their potential to predict the primary outcome within 90 days of follow-up (Table 4 ). In the single predictor Cox proportional hazard analysis, the presence of left ventricular dysfunction (dichotomized), the presence of acute coronary syndrome (dichotomized), PAPP-A (dichoto mized or continuous), C-reactive protein (dichotomized or continuous), creatine kinase (dichotomized), troponin I (dichotomized or continuous) and creatinine (dichotomized or continuous) all predicted major adverse cardiovascular events, whereas sex, age, BMI, number of affected coronary vessels and attributes from the patients' medical history did not (all p ≥ 0.05, Table 4 ). After adjustment for predictors of the primary outcome that were clinically important in the single-predictor model, PAPP-A remained a significant independent predictor of major cardiovascular events (adjusted HR per 1 SD increase in log PAPP-A 1.96, 95% CI 1.74-2.21). Other significant predictors in the adjusted model were a history of diabetes mellitus (adjusted HR 1.49, 95% CI 1.06-2.10) and a history of atrial fibrillation (adjusted HR 0.52, 95% CI 0.29-0.94) ( Table 4) .
PAPP-A remained the strongest predictor of major cardiovascular events when we restricted the analysis to patients with stable angina (adjusted HR per 1 SD increase in log PAPP-A 2.15, 95% CI 1.81-2.56) and when we restricted it to patients with acute coronary syndrome (adjusted HR per 1 SD increase in log PAPP-A 1.91, 95% CI 1.48-2.46). In the multivariable model including the entire cohort, no material change was noted when we analyzed separately the outcomes myocardial (re)infarction (adjusted HR per 1 SD increase in log PAPP-A 1.89, 95% CI 1.60-2.24), ischemic stroke (adjusted HR per 1 SD increase in log PAPP-A 2.15, 95% CI 1.51-3.06) and cardiovascular-related death (adjusted HR per 1 SD increase in log PAPP-A 2.06, 95% CI 1.70-2.49). This finding could not be verified with regard to the outcome stent thrombosis, for which only the presence of left ventricular dysfunction (adjusted HR 2.05, 95% CI 1.05-3.99) and a medical history of diabetes (adjusted HR 3.33, 95% CI 1.78-6.22) proved to be independently predictive. Figure 2 shows the Kaplan-Meier survival curves for patients with PAPP-A below and above the best prognostic cut-off of 34.6 mIU/L, adjusted for all variables shown in the multivariable model in Table 4 (adjusted HR 5.28, 95% CI 3.81-7.31).
Adjusting the main clinical model for the variables that were available only for a limited number of patients (BMI, previous myocardial infarction and previous revascularization) did not change the results with regards to PAPP-A. After adjustment for BMI, PAPP-A remained a significant predictor of the combined primary outcome (adjusted HR per 1 SD increase in log PAPP-A 2.13, 95% CI 1.83-2.49), with BMI also being independently predictive (adjusted HR per 1 kg/m 2 increase 0.94, 95% CI 0.89-0.99). Adjusting the main model for the number of affected coronary vessels, history of myocardial infarction and previous revascularization showed that the primary diagnosis of acute coronary syndrome, the presence of left ventricular dysfunction, a history of diabetes, a history of atrial fibrillation, a C-reactive protein level above the optimal cut-off and PAPP-A were all predictive of the combined primary outcome (adjusted HR per increase in 1 SD of log PAPP-A 1.95, 95% CI 1.57-2.42). The number of affected coronary vessels, history of myocardial infarction and previous revascularization were not predictive in this model.
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Interpretation
Our study showed that PAPP-A was an independent predictor of the combined primary outcome of stent thrombosis, myocardial (re)infarction, ischemic stroke and cardiovascular-related death within 90 days among patients presenting with cardiac chest pain. This finding remained true when we restricted the analysis to include either patients with stable angina or those with acute coronary syndrome.
Similar to other metalloproteinases, PAPP-A could be involved in the processing of the extracellular matrix of arterial plaque and in the weakening of the fibrous cap. 1 5 However, whether PAPP-A acts in a proinflammatory sense or exerts inflammatory suppressor activity is unclear. 15 Also unclear is whether insulin-like growth factor-1, whose availability is increased by PAPP-A, is an anti-or a pro-atherogenic molecule. The fact that only a minority of studies have shown a correlation between PAPP-A and C-reactive protein values casts further doubt on the argument that PAPP-A plays a role in inflammatory reactions. 16 Such a correlation was not noted in our study.
Our findings support the results of earlier studies that suggested PAPP-A as a marker of unstable atherosclerotic plaques, the first of which was published in 2001. 12 In a study by Cosin-Sales and colleagues involving 396 patients with stable angina, 289 of whom had significant coronary artery disease, patients who had complex lesions had higher serum PAPP-A levels than those who did not. 17 Lund and colleagues 18 found that a PAPP-A level above the cut-off of 2.9 mIU/L and a C-reactive protein level above the cutoff of 2.0 mg/L predicted cardiovascular death, myocardial infarction or the need for revascularization within 6 months of follow-up. Heeschen and colleagues analyzed PAPP-A levels in 547 patients with angiographically validated acute coronary syndrome and 644 heterogenous patients presenting with acute chest pain. 19 They found that PAPP-A (optimal cut-off 12.1 mIU/L) was an independent predictor of adverse outcomes in both subgroups of patients.
The difference between the optimal cut-off value in our study and the one calculated by Heeschen and colleagues is probably due to the difference in assays used and length of followup periods. Not all assays developed for the detection of PAPP-A in prenatal screening may be suitable for use in patients with coronary artery disease. 20 Indeed, antibodies used in assays for PAPP-A are all raised by immunization of mice with PAPP-A isolated from human pregnancy serum. However, unlike PAPP-A in patients with coronary artery disease, PAPP-A in pregnancy circulates as a complex with the proform of eosinophil major basic protein (proMBP). Qin and colleagues stated that assays using antibodies against only proMBP fail to detect PAPP-A in patients with acute coronary syndrome. 20 Although the assay used in our study was developed for use in prenatal screening, the fact that PAPP-A levels were detectable in all of the patients supports the view that the assay correctly identified PAPP-A levels in both patient subgroups.
Several authors have investigated the value of PAPP-A for predicting unstable atherosclerotic plaque using either single 16, 17, 21, 22 or serial 23−25 measurements, even in patients receiving hemodialysis. 26 Studies have consistently shown higher PAPP-A levels in patients with acute coronary syndrome or multivessel coronary artery disease than in patients with stable angina or single-vessel disease. 20, 27, 28 Our study also showed higher levels in patients with acute coronary syndrome than in those with stable angina.
Limitations
We analyzed PAPP-A values only from serum samples obtained at baseline. Follow-up samples were not available for our patients. We therefore cannot exclude that peak or follow-up PAPP-A values may have better (or worse) predictive value. In addition, not all patients who present with cardiac chest pain will eventually undergo cardiac catheterization; future studies need to show whether our findings can be applied to these patients as well. Further, we cannot exclude whether PAPP-A might be a better predictor of stent thrombosis if serum samples were drawn just after the procedure; however, in this case, the use of heparin may interfere with PAPP-A assessment. Even though PAPP-A had originally been suggested as a marker of unstable atherosclerotic plaques, 12 our study did not provide direct biological evidence of plaque instability. Another limitation is that we measured total PAPP-A, not the free form. Findings from a previous study suggested that the free form is a stronger predictor of cardiovascular diseases. 29 Although our study had a large cohort, it was conducted in a single centre. A multinational, multicentre study is needed to validate our results.
Conclusion
Higher levels of serum PAPP-A were independently associated with an in creased short-term risk of cardiovascular events in patients presenting with cardiac chest pain. Further studies are required to validate the use of PAPP-A in routine clinical practice to predict future cardiovascular events. If these studies are successful, PAPP-A measurements could play a role in reducing morbidity and mortality from coronary disease.
